Derivation and characterization of a quinapyramine-resistant clone of Trypanosoma congolense.
Over a period of 208 days a quinapyramine-resistant population was derived in vivo from a quinapyramine-susceptible clone of Trypanosoma congolense: IL 1180. While the dose of quinapyramine sulfate required to cure 50% of mice infected with the parental clone was 0.23 mg/kg of body weight, the 50% curative dose for the resistant derivative, IL 1180/Stabilate 12, was greater than 9.6 mg/kg. This approximately 40-fold increase in resistance to quinapyramine was shown to be associated with an 8-fold increase in resistance to isometamidium, a 28-fold increase in resistance to homidium, and a 5.5-fold increase in resistance to diminazene. Cross-resistance to homidium and diminazene was also demonstrated in goats. Two clones derived from the drug-resistant derivative underwent cyclical development in Glossina morsitans centralis, producing mature infection rates of 39.6 and 23.9%. Thus, induction of resistance to quinapyramine in T. congolense IL 1180 was associated with cross-resistance to isometamidium, homidium, and diminazene and did not compromise the population's ability to undergo full cyclical development in tsetse flies.
Ndoutamia
G
G
International Laboratory for Research on Animal Diseases, Nairobi, Kenya.
Moloo
S K
SK
Murphy
N B
NB
Peregrine
A S
AS
D000818:Animals; D002999:Clone Cells / Q000187:drug effects; D004351:Drug Resistance; D006041:Goats; D051379:Mice; D011806:Quinolinium Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D014344:Trypanocidal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D014348:Trypanosoma congolense / Q000187:drug effects* / Q000254:growth & development; D014353:Trypanosomiasis, African / Q000188:drug therapy / Q000469:parasitology / Q000635:transmission
D011806:Quinolinium Compounds; D014344:Trypanocidal Agents; C005707:quinapyramine